Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Enterprise Value (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Enterprise Value readings, the most recent being -$45622.0 for Q3 2025.

  • On a quarterly basis, Enterprise Value fell 859.45% to -$45622.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$45622.0, a 859.45% decrease, with the full-year FY2024 number at -$49404.0, up 7.19% from a year prior.
  • Enterprise Value hit -$45622.0 in Q3 2025 for Goldenwell Biotech, up from -$76507.0 in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$4755.0 in Q3 2024 to a low of -$248569.0 in Q1 2021.
  • Median Enterprise Value over the past 5 years was -$45996.0 (2022), compared with a mean of -$87931.7.
  • Biggest five-year swings in Enterprise Value: surged 82.54% in 2022 and later tumbled 859.45% in 2025.
  • Goldenwell Biotech's Enterprise Value stood at -$213556.0 in 2021, then soared by 78.46% to -$45996.0 in 2022, then fell by 15.73% to -$53231.0 in 2023, then rose by 7.19% to -$49404.0 in 2024, then increased by 7.66% to -$45622.0 in 2025.
  • The last three reported values for Enterprise Value were -$45622.0 (Q3 2025), -$76507.0 (Q2 2025), and -$17127.0 (Q1 2025) per Business Quant data.